Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","amount":"$315.0 million","upfrontCash":"Undisclosed","newsHeadline":"CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$20.0 million","newsHeadline":"LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical Products Administration in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Hasten Biopharmaceutic

    Menu

    Hasten Biopharmaceutic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hasten Biopharmaceutic

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical...

              Details:

              LIB003 (lerodalcibep) is a potential best in class, novel, small binding protein, third-generation PCSK9 inhibitor, which is being evaluated for the treatment and prevention of cardiovascular disease.

              Lead Product(s): Lerodalcibep

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: LIB003

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: LIB Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hasten Biopharmaceutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China

              Details:

              Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize LIB003 (lerodalcibep), a next-generation, PCSK9 inhibitor, for patients at very high and high-risk of cardiovascular disease, in Greater China.

              Lead Product(s): Lerodalcibep

              Therapeutic Area: Genetic Disease Product Name: LIB003

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: LIB Therapeutics

              Deal Size: $325.0 million Upfront Cash: $20.0 million

              Deal Type: Licensing Agreement September 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hasten Biopharmaceutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma

              Details:

              The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, used to treat hypertension.

              Lead Product(s): Azilsartan

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: CBC Group

              Deal Size: $315.0 million Upfront Cash: Undisclosed

              Deal Type: Financing April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY